MYOV NYSE
Myovant Sciences Ltd.
1W: +0.1%
1M: +0.3%
3M: +0.3%
1Y: +137.1%
3Y: +173.6%
5Y: +68.6%
$26.98
Last traded 2023-03-09 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$231M
+289.4% ▲
Gross Profit
$179M
+212.8% ▲
Operating Income
-$187M
+28.2% ▲
Net Income
-$206M
+19.3% ▲
EPS (Diluted)
$-2.22
+21.6% ▲
EBITDA
-$184M
+28.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $59M | $231M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +289.4% |
| Cost of Revenue | $0 | $0 | $0 | $2M | $52M |
| Gross Profit | $0 | $0 | $0 | $57M | $179M |
| Gross Margin | — | — | — | 96.7% | 77.7% |
| R&D Expenses | $117M | $223M | $193M | $137M | $107M |
| SG&A Expenses | $24M | $42M | $82M | $181M | $259M |
| Operating Expenses | $141M | $265M | $275M | $318M | $367M |
| Operating Income | -$141M | -$265M | -$271M | -$261M | -$187M |
| Operating Margin | — | — | — | -439.6% | -81.1% |
| Interest Expense | $2M | $9M | $13M | $10M | $14M |
| Income Before Tax | -$143M | -$273M | -$288M | -$255M | -$201M |
| Tax Expense | $213K | $476K | $761K | $336K | $5M |
| Net Income | -$143M | -$274M | -$289M | -$255M | -$206M |
| Net Margin | — | — | — | -430.1% | -89.2% |
| EPS (Diluted) | $-2.41 | $-4.09 | $-3.37 | $-2.83 | $-2.22 |
| EBITDA | -$141M | -$256M | -$274M | -$242M | -$184M |
| Shares Outstanding | 60M | 67M | 86M | 90M | 93M |